Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Blackstone Inc. (BX)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
123.03+1.00 (+0.82%)
At close: 4:00PM EDT
123.12 +0.09 (+0.07%)
After hours: 07:59PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close122.03
Open123.81
Bid122.50 x 1200
Ask123.00 x 800
Day's Range121.42 - 126.35
52 Week Range49.40 - 136.89
Volume2,816,089
Avg. Volume3,551,009
Market Cap87.482B
Beta (5Y Monthly)1.34
PE Ratio (TTM)22.49
EPS (TTM)5.47
Earnings DateOct 26, 2021 - Nov 01, 2021
Forward Dividend & Yield3.02 (2.67%)
Ex-Dividend DateJul 30, 2021
1y Target Est116.68
  • Zacks

    Blackstone Inc. (BX) Outpaces Stock Market Gains: What You Should Know

    Blackstone Inc. (BX) closed the most recent trading day at $123.03, moving +0.82% from the previous trading session.

  • Business Wire

    Blackstone Announces Appointment of Emily Yoder as Senior Managing Director, Strategic Relationships

    NEW YORK, October 13, 2021--Blackstone today announced the appointment of Emily Yoder as Senior Managing Director, Strategic Relationship Management. She will serve as a primary interface with Blackstone’s banking and other financial services partners. In this newly created role, Ms. Yoder will be responsible for delivering a firm-wide approach to relationship management.

  • Business Wire

    Monika Vnuk and Matt Lane join Blackstone Life Sciences as Managing Directors

    CAMBRIDGE, Mass., October 13, 2021--Blackstone Life Sciences ("BXLS"), Blackstone’s life sciences business, announced today that Dr. Monika Vnuk and Matt Lane have joined BXLS as Managing Directors in the firm’s Cambridge office. Dr. Vnuk joins from Pfizer, where she served as Vice President of Worldwide Business Development, having recently led Pfizer’s partnership with BioNTech for their COVID-19 vaccine. Mr. Lane joins with more than 20 years of experience in advising life sciences companies,

Advertisement
Advertisement